Document is current
Any future updates will be listed below
-
Authors
Godfrey, Laura C https://orcid.org/0000-0002-6222-3563
Regalado, Brandon
Schweber, Sydney R https://orcid.org/0009-0004-2141-7224
Hatton, Charles https://orcid.org/0000-0001-9903-4291
Wenge, Daniela V https://orcid.org/0000-0002-0064-9104
Wen, Yanhe https://orcid.org/0000-0003-3536-6056
Boileau, Meaghan
Wessels, Maria
Qi, Jun
Ott, Christopher J
Stegmaier, Kimberly
Rivera, Miguel N
Armstrong, Scott A https://orcid.org/0000-0002-9099-4728
-
Funding
Funding for this research was provided by:
HHS | National Institutes of Health (CA231637)
Deutsche Forschungsgemeinschaft (511811315)
FRQ | Fonds de Recherche du Québec - Santé (Bf7-326051)
- License Information
-
More Information
Article History
Received: 4 October 2024
Revised: 11 July 2025
Accepted: 4 August 2025
First Online: 1 September 2025
Disclosure and competing interests statement
: SAA has been a consultant and/or shareholder for Neomorph Inc., C4 Therapeutics, Accent Therapeutics, Nimbus Therapeutics, AstraZeneca and Hyku Therapeutics. SAA has received research support from Janssen and Syndax. SAA is an inventor on a patent application related to MENIN inhibition WO/2017/132398A1. KS received grant funding from the DFCI/Novartis Drug Discovery Program and from KronosBio and is a member of the SAB and has stock options with Auron Therapeutics on topics unrelated to this work.
